Dimethylethanolamine Decreases Epileptiform Activity in Acute Human Hippocampal Slices in vitro by Kraus, Larissa et al.
BRIEF RESEARCH REPORT




Daegu Gyeongbuk Institute of




Institute of Evolutionary Physiology
and Biochemistry (RAS), Russia
Giuseppe Biagini,





Received: 19 May 2019
Accepted: 09 August 2019
Published: 06 September 2019
Citation:
Kraus L, Hetsch F, Schneider UC,
Radbruch H, Holtkamp M, Meier JC
and Fidzinski P
(2019) Dimethylethanolamine
Decreases Epileptiform Activity in
Acute Human Hippocampal
Slices in vitro.
Front. Mol. Neurosci. 12:209.
doi: 10.3389/fnmol.2019.00209
Dimethylethanolamine Decreases
Epileptiform Activity in Acute Human
Hippocampal Slices in vitro
Larissa Kraus1,2, Florian Hetsch3, Ulf C. Schneider4, Helena Radbruch5,
Martin Holtkamp1,2, Jochen C. Meier2,3 and Pawel Fidzinski1*
1Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin
Institute of Health, Department of Neurology with Experimental Neurology, Berlin, Germany, 2Berlin Institute of Health (BIH),
Zoologisches Institut, Technische Universität Braunschweig, Braunschweig, Germany, 3Zoologisches Institut, Technische
Universität Braunschweig, Braunschweig, Germany, 4Charité-Universitätsmedizin Berlin, corporate member of Freie
Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neurosurgery, Berlin,
Germany, 5Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin,
and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy with about
30% of patients developing pharmacoresistance. These patients continue to suffer from
seizures despite polytherapy with antiepileptic drugs (AEDs) and have an increased
risk for premature death, thus requiring further efforts for the development of new
antiepileptic therapies. The molecule dimethylethanolamine (DMEA) has been tested as
a potential treatment in various neurological diseases, albeit the functional mechanism of
action was never fully understood. In this study, we investigated the effects of DMEA on
neuronal activity in single-cell recordings of primary neuronal cultures. DMEA decreased
the frequency of spontaneous synaptic events in a concentration-dependent manner
with no apparent effect on resting membrane potential (RMP) or action potential (AP)
threshold. We further tested whether DMEA can exert antiepileptic effects in human brain
tissue ex vivo. We analyzed the effect of DMEA on epileptiform activity in the CA1 region
of the resected hippocampus of TLE patients in vitro by recording extracellular field
potentials in the pyramidal cell layer. Epileptiform burst activity in resected hippocampal
tissue from TLE patients remained stable over several hours and was pharmacologically
suppressed by lacosamide, demonstrating the applicability of our platform to test
antiepileptic efficacy. Similar to lacosamide, DMEA also suppressed epileptiform activity
in the majority of samples, albeit with variable interindividual effects. In conclusion, DMEA
might present a new approach for treatment in pharmacoresistant TLE and further
studies will be required to identify its exact mechanism of action and the involved
molecular targets.
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INTRODUCTION
Epilepsy is a major neurological disorder affecting up to 65 million people worldwide (Hirtz
et al., 2007; Ngugi et al., 2010). The need for adequate treatment is not only given by seizures
itself along with associated risks of injury and premature death but also by comorbidities
and social stigmatization. Specifically in focal epilepsy, 30%–40% of patients do not respond to
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currently available antiepileptic drugs (AEDs), resulting in
pharmacoresistance with ongoing seizures despite treatments
with multiple AEDs at high dosages (Stephen et al., 2001).
Alternative therapies such as ketogenic diet or brain
stimulation have been suggested to reduce seizure burden in
pharmacoresistant patients (Giordano et al., 2014; Kowski et al.,
2015; Dibué-Adjei et al., 2019). However, ketogenic diet has been
shown to be effective in children and with modification in adults
but is still rarely considered as treatment in adults (Hallböök
et al., 2015; Falco-Walter et al., 2019). Ongoing investigations
show promising seizure reduction in pharmacoresistant patients
by deep brain stimulation (Zangiabadi et al., 2019). However,
this approach requires optimal selection of targeted brain regions
and prospective trials are lacking. Finally, surgical removal of
the epileptic focus remains often the only treatment option
for pharmacoresistant patients (Wiebe et al., 2001; Engel et al.,
2007). Yet, only in a minority of patients, epilepsy is amenable to
surgery, and only 60%–70% of resected patients have a positive
outcome with substantial reduction of the seizure burden
(International League Against Epilepsy Outcome Scale 1–2;
Mohan et al., 2018). Thus, identification of new antiepileptic
treatment options in focal pharmacoresistant epilepsy is of
paramount importance.
Dimethylethanolamine (DMEA) has previously been
investigated as a stimulant and treatment for several neurological
diseases, including tardive dyskinesia (TD), Alzheimer’s disease
(AD) and senile dementia (Ferris et al., 1977; Penovich et al.,
1978; de Montigny et al., 1979; Fisman et al., 1981; George
et al., 1981). First, application of DMEA to human healthy
volunteers dates back to the 1960s when DMEA was reported
to exert stimulating effects comparable to amphetamine
(Murphree et al., 1960; Pfeiffer et al., 1963). Murphree et al.
(1960) described improved concentration, increased muscle
tone and changed sleeping habits in healthy males (21–26 years)
with an intake of 10–20 mg DMEA (or Deanol) daily for
2–3 weeks compared to a placebo group. In later studies, DMEA
was hypothesized as an acetylcholine (ACh) precursor and
therefore tested in diseases that are considered to be linked to
the cholinergic system. However, results of several studies were
inconclusive and a systematic review could not confirm the
positive effects of DMEA or other cholinergic compounds in
patients with TD (Tammenmaa et al., 2004). In addition, in vivo
experiments showed that DMEA is not methylated to choline
and does not alter brain ACh levels (Millington et al., 1978;
Jope and Jenden, 1979).
Interestingly, in both acute and chronic seizure models in rats,
a conjugate of DMEA and valproate (DEVA) was shown to be
more potent than valproate alone, potentially by facilitation of
valproate transport via the blood brain barrier (Shekh-Ahmad
et al., 2012). In this study, however, the effects of DMEA
alone were not tested. To our knowledge, effects of DMEA
on pathological neuronal network activity have never been
investigated before.
In principle, resected human tissue of temporal lobe epilepsy
(TLE) patients carries the potential to bridge the translational
gap between preclinical and clinical drug development. Animal
models have been instrumental in the discovery and preclinical
development of novel AEDs (Löscher, 2011). However, animal
models cannot represent all aspects of complex neurological
disorders and sometimes produce misleading results as
exemplified by the neuropeptide galanin. Galanin showed
robust antiepileptic effects in a mouse model of epilepsy,
however, the effect could not be reproduced in resected human
tissue (Ledri et al., 2015).
Here, we decided to investigate the effects of DMEA on
epileptiform activity directly in ex vivo human tissue resected
from epilepsy patients.
MATERIALS AND METHODS
Primary Rat Hippocampal Neuronal Cell
Culture
Hippocampal cultures from E18 Wistar rat embryos were
prepared as previously described (Winkelmann et al., 2014)
according to the approval by the Animal Care Committee of
the Technical University Braunschweig (Zentrale Einrichtung
für Tierhaltung der TU Braunschweig, §4 10.15.R TSB TU
BS) and maintained in Neurobasal medium supplemented with
B27 and 1% FCS (Brewer et al., 1993). Hippocampal neurons
were subjected to whole cell patch clamp analysis at DIV13–16




An EPC-7 amplifier (List-Medical, Darmstadt, Germany),
ITC-18 interface and Patchmaster software (both HEKA,
Lamprecht, Germany) were used for patch clamp recordings
and data acquisition. Patch pipettes made from borosilicate
glass (Science Products, Hofheim, Germany), had resistances of
4–7 M when filled with the intracellular solution containing
(in mM): KCl (130), NaCl (5), CaCl2 (0.5), MgCl2 (1), EGTA
(5) and HEPES (30), pH 7.2 (KOH). Neurons were continuously
perfused with carbogenated artificial cerebrospinal fluid (aCSF)
containing (in mM): NaCl (125), KCl (2), MgCl2 (1), CaCl2
(2), NaHCO3 (25), NaH2PO4 (1.25) and glucose (10), pH 7.4.
Extracellular solution was supplied by gravity using a perfusion
pencil (Automate Scientific Inc., Berkeley, CA, USA) for fast
solution exchange. The extracellular solution was supplemented
with 0.5, 2, 5 or 10 mM DMEA. Series resistances (Rs) were
monitored by 5 mV voltage pulses (50 ms) applied every 5 s and
varied between 10 M and 30 M. Data were acquired with a
sampling rate of 20 kHz and filtered at 2.8 kHz. All experiments
were carried out at room temperature (∼24◦C).
The effect of DMEA on synaptic activity and excitability was
tested in current-clamp mode with stepwise increase of DMEA
concentration. DMEA was applied for 60 s, following 3–5 min
wash-out with aCSF before applying the next drug concentration.
No synaptic or intrinsic blockers were added. A steady current
injected into the cell was used to hold the membrane potential
around −50 mV never exceeded 150 pA. Action potential (AP)
threshold was investigated by short current injections using
10 pA steps with or without the application of DMEA. AP
threshold was determined as the mean between the minimum
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membrane potential necessary for AP generation and membrane
potential of the previous step current.
Human Tissue Transport and Preparation
Human hippocampal tissue from epilepsy surgery was
collected from 12 TLE patients (10 males, two females),
who all gave written consent prior to the procedure.
Experiments were approved by the Ethics Committee of
Charité-Universitätsmedizin Berlin on the 1st of November 2014
(EA2/111/14) and performed in agreement with the Declaration
of Helsinki.
Hippocampal tissue was transferred to carbonated (95% O2,
5% CO2), ice-cold transport solution immediately after resection.
Tissue was transported to the lab in <60 min and cut to
400 µm slices using a vibratome (Leica VT1200S, Wetzlar,
Germany). N-methyl d-glucamine (NMDG)-aCSF was used for
brain tissue transport and slice preparation from patients 1–7,
while choline-aCSF was used to handle tissue of patient 8–12 in
order to optimize transport. NMDG-aCSF contained (in mM):
NMDG (93), KCl (2.5), NaH2PO4 (1.2), NaHCO3 (30), MgSO4
(10), CaCl2 (0.5), HEPES (20), glucose (25), Na-L-ascorbate (5),
thiourea (2), Na-pyruvate (3; Ting et al., 2014). Choline-aCSF
contained (in mM): Choline chloride (110), KCl (2.5), NaH2PO4
(1.25), NaHCO3 (26), MgCl2 (7), CaCl2 (0.5), glucose (10), Na-
L-ascorbate (11.6), Na-pyruvate (3.1; Testa-Silva et al., 2010).
As part of the standard clinical routine, every third
slice collected during the slicing procedure was fixed in 4%
paraformaldehyde (PFA, pH 7.4, phosphate-buffered saline) and
analyzed for pathological alterations. For electrophysiological
recordings, slices were stored in an interface chamber for a
recovery period of at least 5 h and continuously perfused with
carbogenated aCSF containing (in mM): NaCl (129), NaH2PO4
(1.25), CaCl2 (1.6), KCl (3.0), MgSO4 (1.8), NaHCO3 (21),
Glucose (10; 1.6 ml/min, 35◦C, pH 7.4). All slices were studied
between 6 h and 20 h after resection.
Electrophysiological Recordings of Human
Tissue
For electrophysiological recordings, slices were transferred to a
custom modified version of the membrane chamber (Hill and
Greenfield, 2011) and perfused with aCSF (10 ml/min, 32◦C).
The membrane chamber is a submerged-type recording chamber
with a high flow rate but stable slice position, guaranteeing
optimal oxygen supply and fast drug applications. Field potential
recordings were performed with borosilicate pipettes (1.5 mm
outer diameter, Science Products, Hofheim, Germany) pulled
with a vertical puller (1–2 M, PC-10, Narishige, Tokyo,
Japan) and filled with NaCl (154 mM). Signals were recorded
from CA1 pyramidal cell layer, sampled at 10 kHz, low-pass
filtered at 2 kHz by a Digidata 1550 interface and processed by
PClamp10 software (Molecular Devices, Sunnyvale, CA, USA).
Induction of epileptiform activity in rodent brain slices can
be achieved by a stand-alone manipulation such as inhibition
of potassium channels by 4-aminopyridine (4-AP; Perreault and
Avoli, 1991; Avoli et al., 2002; Heuzeroth et al., 2019). On
the contrary, induction of epileptiform activity in human brain
tissue ex vivo is less straightforward and subject to controversy.
In resected human brain tissue only application of 4-AP in
combination with electrical stimulation or elevated extracellular
potassium was able to show stable induction of epileptiform
activity, not application of 10 or 12 mM potassium or 4-AP alone
(Gabriel et al., 2004; Antonio et al., 2016). Here, we used bath
application of high potassium (8mM) and 4-AP (100µM, Sigma,
Munich, Germany) for the induction of epileptiform activity
in human brain tissue. Increase of osmolarity by 8 mM KCl
was balanced by lowering NaCl concentration from 129 mM to
124 mM.
Baseline epileptiform activity was recorded for ≥20 min.
DMEA (10 mM, Sigma, Munich, Germany) or lacosamide
(LAC, 100 µM, Biozol, Eching, Germany) were then applied
for ≥20 min, followed by ≥20 min of wash-out. In initial
experiments we tested 5 mM and 10 mM of DMEA in the same
slice, starting with 5 mM DMEA (20 min), followed by 10 mM
DMEA and wash-out as described above.
Addition of DMEA increases osmolarity of aCSF possibly
affecting neuronal activity. Therefore, we performed control
experiments with increasing the osmolarity of aCSF up to
∼310 mOsm by addition of 10 mM sucrose (patients 10, 11,
and 12). This approach has been used to test hyperosmolar
solutions before (Rosenmund and Stevens, 1996). Here, the
recording sequence stated above was modified and consisted of
the following steps: (1) baseline with stable epileptiform activity
(≥10 min); (2) 10 mM sucrose (≥20 min); and (3) wash-out
sucrose (≥10 min), 10 mM DMEA (≥20 min), wash-out DMEA
(≥20 min).
Data Analysis and Statistics
Electrophysiological data recorded in single cells from primary
neuronal cell cultures was quantified and measured using an
IGOR Pro (Version 6.3.7.2, Wavemetrics Inc., Oregon, USA)
procedure written by Dr. Marcus Semtner (MDC Berlin) and the
extension PatchersPowerTools (written by Dr. FranciscoMendez
and Frank Würriehausen).
Recordings in human hippocampal tissue were band pass
filtered (1–1,000 Hz) and the 300 s long episodes (last 5 min
of each application phase) were analyzed with Clampfit 10.7
(Molecular Devices, Sunnyvale, CA, USA) threshold analysis. All
events visually identified as burst activity (defined by biphasic,
positive and negative deflection and a duration ≥100 ms) were
manually indicated for further analysis of event frequency (inter-
event-interval, IEI), amplitude and total number of events during
the analyzed time frame. Interictal spikes (defined by exclusive
negative deflections and a duration <10 ms) were not analyzed.
According to literature, interictal spikes, although pathologically
relevant, are not significantly affected by AEDs (Spencer et al.,
2008; D’Antuono et al., 2010).
All data were analyzed with GraphPad Prism 5 (GraphPad
Software Inc., San Diego, CA, USA). Prior to analysis, data were
subjected to D’Agostino and Pearson omnibus normality test
and analyzed accordingly. In cases where sample size of tested
groups was too small for evaluation of data distribution, data
were analyzed using non-parametric tests.
Statistical analysis of normal distributed data was performed
using repeated measurement analysis of variance (ANOVA)
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and post hoc Tukey’s comparison of all groups. Non-normal
distributed data or data with small sample size was analyzed
either using Friedman test and post hoc Dunnett’s multiple
comparison of individual groups or Wilcoxon signed-rank
test. For all analysis, a p-value < 0.05 was considered
statistically significant.
Data analyzed by parametric tests were presented as scatter
plots with mean ± standard deviation (SD) while data analyzed
by non-parametric tests were presented as scatterplots with
median and interquartile range. Due to IEI variance during
drug application (DMEA or LAC), frequency of events for
all patients was summarized as number of events. IEI for
individual recordings is presented as boxplots with median and
Tukey whiskers (1.5× the interquartile distance) to show data
distribution and inter-individual differences.
Human datasets analyzed in this study can be
found in figshare repository (https://doi.org/10.6084/m9.
figshare.8148572).
RESULTS
To investigate whether DMEA affects neuronal activity and
to obtain information about potential molecular targets, we
performed electrophysiological recordings in primary neuronal
cultures. DMEA dose-dependently reduced spontaneous
synaptic events and associated APs with an estimated EC50 of
∼0.5–1.0 mM. A full block of activity was observed in
all recorded cells when using 5 mM or 10 mM DMEA
(Figures 1A,B,D,E). Neither resting membrane potential
(RMP) nor AP threshold changed upon DMEA application
(Figures 1C,F, Supplementary Figures S1A,B), suggesting
that intrinsic properties do not represent the main target of
DMEA action.
We also investigated the effects of DMEA on epileptiform
activity in hippocampal tissue resected from 12 patients
undergoing epilepsy surgery. Histopathology of resected
tissue revealed distinct pathologies: malformations of cortical
development (MCD) were diagnosed in two patients [mild MCD
changes in one and clear focal cortical dysplasia (FCD) in the
other patient], unspecific astrogliosis in three patients and clear
pathological changes indicating hippocampal sclerosis (HS)
in seven patients (Supplementary Table S1). The changes in
pyramidal layers of CA1, CA3 and CA4 included<10% neuronal
cell loss in three patients (Wyler grade 1), up to 50% cell loss in
three patients (Wyler grade 2) and more than 50% cell loss in
one patient (Wyler grade 3).
From these 12 resected samples, a total of 30 hippocampal
slices was used for electrophysiological recordings. After slice
recovery, we tested our experimental approach by assessing
whether: (1) epileptiform activity in human slices can be induced
by elevated potassium and 4-AP; (2) whether this activity is stable
for prolonged periods of time; and (3) sensitive to conventional
AEDs. In 27 slices from 12 patients, both interictal spikes and
ictal burst activity (Figures 2A,B) could be induced within a few
minutes (Figures 2C,F). In three slices from three patients, burst
events did not occur within 20 min, therefore these slices were
excluded from the analysis.
In control recordings without drug application, the
pathologically relevant burst activity was stable for at
least 60 min (tested in three slices from three patients),
suggesting good viability of human slices in our experimental
setting. In more detail, both frequency and amplitude of
burst activity did not change in most cases during the
recording as indicated by stable IEI, amplitude and number of
burst events (Figures 2D,E).
To test whether burst activity was sensitive to conventional
AEDs, we investigated the effect of the sodium channel blocker
LAC. During application of LAC, IEI increased in all recorded
slices, which was reversible in three out of four patients
(Figure 2G). Number of events of all recordings decreased
during LAC application when compared to baseline activity,
while amplitude of burst activity did not change (Figure 2H). In
conclusion, we were able to induce stable epileptiform activity
that can be inhibited by clinically approved AEDs.
Next, we investigated the effects of DMEA in 14 hippocampal
slices from 10 TLE patients. In initial experiments, we tested
the effects of 5 mM and 10 mM DMEA within one experiment
(Supplementary Figure S2). As the inhibitory effect was
more robust when using 10 mM DMEA (Supplementary
Figure S2B, p < 0.05, n = 6; tested in patients 2–7), we
decided to perform subsequent experiments with this effective
concentration. In contrast to LAC, DMEA effects varied
considerably between samples ranging from no effect (patient 8,
Figure 3A) or only a moderate effect observed in slices
of patient 7 (Figure 3B) to a full block of burst activity
(Figure 3C) in four slices from patients 9, 10 and 11. Irrespective
of the effect variability, DMEA displayed antiepileptic effects
in 10 out of 11 patients (Figure 4A), as indicated by the
increase of IEI and a significant decrease of number of events
during application of DMEA (Figure 4B, p < 0.01, n = 10).
In eight patients, these effects were clearly reversible upon
wash-out of DMEA. Amplitude of epileptiform bursts was not
affected (Figure 4C).
Addition of DMEA at 10 mM increases osmolarity of
the extracellular environment (here, aCSF) which could
possibly decrease epileptiform activity simply by osmotic
effects (Traynelis and Dingledine, 1989; Dudek et al., 1990).
To test whether DMEA effects are mediated by mechanisms
beyond pure change in osmolarity, we investigated how
sucrose and DMEA affect epileptiform activity in the same
slice when applied sequentially. In six slices of three patients
increase of osmolarity by sucrose (310 ± 5 mOsm) to match
osmolarity of solutions containing 10 mM DMEA resulted
in a weak increase of IEI and a weak decrease of number of
events (Supplementary Figure S3). This decrease matched the
observed decrease without intervention over time as shown
in Figure 2E and was likely due to a slow decay in activity in
the course of in vitro experiments. The mild effect of sucrose
application stood in contrast to a full block of activity during
subsequent application of DMEA in patients 10 and 11 and
a strong decrease of activity in patient 12 (Supplementary
Figures S3A,B).
In summary, in human brain slices DMEA exerted
antiepileptic effects presented as an overall decrease in frequency
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 September 2019 | Volume 12 | Article 209
Kraus et al. DMEA in TLE
FIGURE 1 | Dimethylethanolamine (DMEA) decreases spontaneous neuronal activity in neuronal cultures in a concentration-dependent manner. Activity of cultured
hippocampal neurons (DIV 13–16) was investigated in current-clamp mode in the absence or presence of DMEA. During baseline conditions, all neurons displayed
excitatory synaptic events with associated action potentials (APs) at a frequency of ∼1 Hz. Both AP, as well as large amplitude synaptic event frequency, decreased
with increasing DMEA concentration to reach a full block with 5 mM DMEA. (A,D) Exemplary recordings in neurons with application of 0.0, 0.5, 2.0 and 5.0 mM
DMEA (A) or 10 mM DMEA (D); note that due to experimental setup we could not perform repeated measurement in one cell including all concentrations and
present the results here separately; Dashed lines below recordings indicate resting membrane potential (RMP, in mV) of cells. (B,E) DMEA significantly decreases
event frequency in a concentration-dependent manner. (C,F) Application of DMEA does not affect RMP. All data are shown as scatter plots with median and
interquartile range. Asterisks mark significant differences as assessed by Friedman test and post hoc by Dunnett’s multiple comparison of groups (B,C) or by
Wilcoxon signed-rank test (E,F; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Scale bar: 10 mV, 0.5 s.
of burst events, which were not due to osmotic changes. A
summary of all results is presented in Supplementary Table S2.
DISCUSSION
In the present study, we investigated the effect of DMEA on
spontaneous activity in neuronal cultures and on epileptiform
activity in human hippocampal tissue ex vivo. We were able
to show a decrease of spontaneous activity in rodent neuronal
cultures. In the majority of investigated human slices, DMEA
displayed strong antiepileptic effects including full block of burst
activity in slices of three patients. The effect of DMEA in human
tissue varied considerably, implying interindividual differences
in expression patterns of molecular DMEA targets.
The mechanism of DMEA action is not known. Our
preliminary experiments in neuronal cultures showing
dose-dependent inhibition of spontaneous neuronal activity
without altering RMP or AP threshold suggest that DMEA likely
affects synaptic but not intrinsic excitability. In previous clinical
studies, DMEA was tested as a potential ACh precursor but did
not improve disease symptoms in TD or AD. DMEA increased
choline concentrations in plasma and brain though this did
not affect brain ACh concentrations, questioning a beneficial
effect of DMEA in diseases involving the cholinergic system
(Millington et al., 1978; Jope and Jenden, 1979). Nevertheless,
due to structural similarities of DMEA, ACh and choline,
muscarinic ACh receptors (mAChRs) present possible targets
of DMEA action. ACh and choline are both ligands of M2 and
M3 mAChRs (Shi et al., 2004; Moreno-Galindo et al., 2016),
which upon activation increase the open probability of G-protein
coupled inwardly rectifying potassium (GIRK) channels,
specifically GIRK1 and GIRK4 (Nemec et al., 1999). GIRK1 and
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FIGURE 2 | Epileptic burst activity in human slices is stable over long time periods and decreases during application of lacosamide. Application of 8 mM K+ and
100 µM 4-aminopyridine (4-AP) induces two patterns of network activity recorded by field potential electrodes in the CA1 area of human hippocampal slices:
interictal spikes (A) and burst activity (B). (C–E) Burst activity is induced a few minutes after application and stable for at least 60 min. (F–H) Induced burst activity
decreases during application of lacosamide (LAC). (C,F) Exemplary recording with excerpts of regions used for analysis. (D,G) Inter-event intervals (IEI) of individual
recordings shown as box plots with mean and 1.5× interquartile distance. Each dot represents data point outside the 1.5× interquartile distance. Total number of IEI
during analyzed time frame are indicated in brackets. (E,H) Summarized results for all patients [number of events and amplitude as mean ± standard deviation (SD)];
each dot indicates one patient. Asterisks mark significant differences as assessed by Friedman test and post hoc with Dunnett’s multiple comparison of groups
(p < 0.05). T1, T2, T3 in (D,E) are periods analyzed for each patient, comparable to analyzed times in (G,H) and Figure 3. Scale bars: 0.2 mV, 500 ms (A,B), 5 min
(full recording, C), 2 min (full recording, F), 5 s (excerpts, C,F).
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FIGURE 3 | Effects of DMEA on epileptiform activity in human brain tissue ex vivo. Example traces displaying variability of DMEA effects on burst activity; full
recordings (top) and excerpts (bottom) from the end of each period (baseline, DMEA and wash-out) demonstrate different effects of DMEA including a lack of
response (A, patient 8), a partial block (B, patient 7) and a full block (C, patient 11). Scale bars: 0.2 mV, 3 min (full recordings), 1 s (excerpts).
GIRK4 are expressed in the hippocampus (Miyashita and
Kubo, 1997; Murer et al., 1997; Cea-del Rio et al., 2010) and
pharmacological activation of GIRK results in antiepileptic
effects in vitro and in vivo (Kaufmann et al., 2013). Thus, M2 or
M3 mAChRs and GIRK channels present a possible mechanism
for DMEA action.
Another possible candidate are glycine receptors (GlyR). In
a separate project, our group analyzed the effects of DMEA
on GlyR, which has been described as subject to increased
RNA editing in TLE (Krestel et al., 2013; Winkelmann et al.,
2014; Meier et al., 2016; Srivastava et al., 2017). Presynaptic
RNA-edited GlyR facilitates neurotransmitter release resulting
in increased neuronal gain and, depending on the neuronal
subtype, network hyper- or hypoexcitability (Winkelmann
et al., 2014; Caliskan et al., 2016). In an initial screen
for antagonists against RNA-edited GlyR (data not shown),
DMEA was considered as a candidate giving an additional
incentive to test this substance in human brain slices. However,
confirmatory experiments were not able to reproduce DMEA
specificity against RNA-edited GlyR. Overall, the molecular
targets of DMEA and its mechanism of action in brain tissue
remain indeterminate.
The main goal of our study was to demonstrate a
possibly clinically relevant effect of DMEA. DMEA has
been tested in patients and healthy volunteers since 1960s
(Murphree et al., 1960; Pfeiffer et al., 1963). In healthy males,
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FIGURE 4 | DMEA reduces epileptiform activity in human hippocampal slices. Summary of DMEA effects on burst activity recorded in CA1 pyramidal cell layer of
resected human hippocampus. (A) Box plots of IEIs with mean and 1.5× interquartile distance before, during and after DMEA application for each patient are shown
for all recorded slices (n = 10 patients). Dots represent data points outside the 1.5× interquartile distance. Total number of IEI during analyzed time frame are
indicated in brackets. (B) Summary of DMEA effects on number and (C) amplitude of burst events for all patients; each dot indicates one patient. Data is presented
as scatter plots with mean ± SD, asterisks mark significant differences as assessed by repeated measurement analysis of variance (ANOVA) and post hoc with
Tukey’s comparison (∗∗p < 0.01, n = 10).
Murphree et al. (1960) reported no change in heart rate,
body weight, muscle power, hand steadiness or vital capacity
with an intake of 10–20 mg DMEA (or Deanol) daily for
2–3 weeks. In two double-blinded, placebo-controlled studies
of TD, DMEA led to side effects such as lethargy, drowsiness
and a mild but significant increase in the schizophrenia score
(de Montigny et al., 1979; George et al., 1981), although
a systematic review was not able to confirm an increased
risk for psychosis (Tammenmaa et al., 2004). Fisman et al.
(1981) detected severe neurological and cardiovascular effects
(apathy, motor retardation, increased confusion associated with
rise in systolic and diastolic blood pressure) in two patients
with AD when treated with 1,800 mg DMEA daily. In these
studies, as compared to Murphree et al. (1960), DMEA was
administered in a 100-fold higher daily dosage (10–20 mg vs.
1,000–2,000 mg). A dose of 2,000 mg DMEA corresponds to
a molar amount of 22 mM and a final in vivo concentration
of 0.44 mM assuming a distribution across all compartments
and a body water content of approximately 50 l for an adult
male. This concentration is lower by a factor of 20 when
compared to 10 mM tested to be effective in human brain
tissue ex vivo in our study, and this difference is rather
underestimated when taking into account oral bioavailability.
Of note, in neuronal cultures, the effective concentration to
inhibit neuronal activity was lower by a factor of 10, implying
that differences in microenvironment, neuronal connectivity
and drug diffusion in different preparations and species might
influence the effective concentration.
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Addition of DMEA to our experimental solution increased
the osmolarity by ∼10 mOsm. In previous studies, application
of hyperosmolar solutions decreased neuronal excitability and
epileptiform activity, but in most cases, an increase of 30 mOsm
and more was necessary to induce these effects (Traynelis
and Dingledine, 1989; Dudek et al., 1990; Rosen and Andrew,
1990). According to Rosen and Andrew (1990), an increase of
extracellular osmolarity by 10 mOsm might result in a 10%
decrease of EPSC amplitude in CA1 pyramidal neurons, but the
effects of such EPSC alteration on network activity have not been
investigated. Here, increase of aCSF osmolarity by application of
10 mM sucrose did not alter epileptiform activity, indicating that
the antiepileptic effects of DMEA are not primarily mediated by
changes in osmolarity.
Although our study clearly demonstrated an antiepileptic
effect of DMEA, the large concentration difference between
our work and previous clinical studies and the variability of
underlying pathologies represent substantial limitations. The
results suggest heterogeneous expression of DMEA targets,
however, also differences in neuronal survival and the degree
of HS could possibly contribute. An additional limitation
is given by different transport solutions used in our study,
namely either NMDG or choline aCSF (Testa-Silva et al.,
2010; Eyal et al., 2018; Ting et al., 2018). Although we
were unable to detect differences in tissue quality as seen
by stable induction and properties of epileptiform activity,
we cannot exclude differences in neuronal survival between
these solutions.
The predictive value of brain activity for drug development
in an ex vivo setting is still unclear. In our approach
using a modified submerged chamber, we mostly observed
burst activity (spike and burst activity) described before
as interictal-like (Remy et al., 2003; Gabriel et al., 2004;
Sandow et al., 2015; Reyes-Garcia et al., 2018) and standing
in contrast to ictal discharges lasting >10 s. Brückner and
Heinemann (2000) suggested that AEDs applied in brain
slices (of non-epileptic animals) rather inhibit ictal but not
interictal activity. Other animal studies in vitro, however,
demonstrated a robust decrease in interictal activity in the
hippocampus upon AED application (Fueta and Avoli, 1992;
Holtkamp et al., 2017; Taing et al., 2017), which was
comparable to our results with LAC and DMEA. We show
that burst activity was sensitive to the approved antiepileptic
LAC, indicating that our experimental setting is capable of
validating and possibly predicting antiepileptic efficacy for
drug development.
Taken together, our work identified the antiepileptic effect
of DMEA in human hippocampal tissue from TLE patients.
Interindividual effect variability, differences in the effective
concentration range and previously reported side effects call for
future, more detailed investigation of cell-type specific effects and
molecular targets of DMEA.
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FIGURE S1 | DMEA does not change action potential threshold. Application of
10 mM DMEA does not change threshold for AP generation. (A) Exemplary
recordings of patch-clamp recordings in current-clamp mode with step current
without AP (first for each) and with AP generation (second); dashed lines below
recordings show −60 mV value to indicate RMP of cells. (B) Quantified effect of
DMEA on AP threshold in neurons. Data are shown as median with interquartile
range and was subjected to Wilcoxon signed-rank test; n = 6.
FIGURE S2 | Dose-dependent effects of DMEA on epileptiform activity in human
hippocampal slices. (A) Box plots of inter-event intervals (IEI) during baseline,
5 mM DMEA, 10 mM DMEA and wash-out for each patient given for all recorded
slices (n = 6 patients). In all experiments, both concentrations were applied in the
same brain slice. Box plots are shown with mean and Tukey whiskers (1.5×
interquartile distance). Each dot represents a data point outside the 1.5×
interquartile distance. Total number of IEI during analyzed time frame are indicated
in brackets. (B) Summary of DMEA effects on the number and amplitude of burst
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events for all tested patients; each dot indicates one patient. Data are presented
as scatter plots with median ± interquartile range. Asterisks mark significant
differences as assessed by Friedman test and post hoc with Dunnett’s multiple
comparison of groups (∗p < 0.05).
FIGURE S3 | Increase of osmolarity by 10 mOsm does not affect epileptiform
activity. For control purposes, sucrose was used to increase osmolarity and
applied in the same slice before DMEA application. (A) Full time course and
detailed excerpts of exemplary recording used for the analysis of potential
hyperosmotic effects of DMEA on epileptiform activity. Note that sucrose
application leading to the same osmotic change as DMEA does not significantly
alter epileptiform activity, while DMEA application in the same slice clearly exerts
an antiepileptic effect. (B) Inter-event intervals of individual recordings shown as
box plots with a total number of IEI during analyzed time frames indicated in
brackets. (C) Summarized number of events and amplitudes for all patients
presented as scatterplots with median and interquartile range; each dot indicates
one patient. Scale bars: 0.2 mV, 5 min (full recordings), 5 s (excerpts).
TABLE S1 | Clinical data of patients, who provided tissue for
electrophysiological assessment of the effects of DMEA on epileptic activity.
TABLE S2 | Summarized results of burst activity in human tissue during
application of DMEA, LAC, no intervention or sucrose as control for
osmolarity effects.
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